TGTX - Earnings call transcript Q1 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the TG Therapeutics Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jenna Bosco. Thank you, Jenna.

You may begin.

Jenna Bosco

Thank you. for this thanks and everyone, joining morning. us Welcome, Waldman, me discuss are Sean the Jenna Officer; Weiss, Bosco, quarter Power, to with and Adam Executive Officer. Chief results I'm our first Chief Officer; today XXXX Chairman and Chief Financial our Commercialization our and Michael financial

results will of harbor Sean session. turning on of our begin before efforts, an and our our share recent to Following our to provide will update safe corporate give an overview an will financial statement, Mike over operator call overview development, Adam the commercialization the Q&A the

Before statements to the milestones, our will meaning products. begin, and our and operating about These Reform including everyone within be Private plans expectations the for that XXXX. Securities Litigation anticipated performance, clinical future we we or I'd performance, projected like regulatory of Act revenue financial statements include making sales marketed development statements forward-looking guidance, of remind forward-looking

to results TG that that cautions that be risks include indicated. TG differ from may SEC our to various cause affect Factors that our Therapeutics filings. may those these found factors can forward-looking operations materially statements are risk subject in actual

update forward-looking today revise as as our call on made only as or any later date. relied views any of forward-looking any of In this to representing disclaim any and addition, obligation be statements not views statements. should represent upon our specifically We

our TG's rebroadcast call the conference the I'd www.tgtherapeutics.com, This Mike to next that, recorded With on it to website, days. like will over being audio for available Weiss, XX call where be for is CEO. turn

Michael Weiss

on everyone, and today's and good call. for thanks Great. morning, joining Thanks, us Jenna,

example this contract the we and an exciting I'm VA cylinders. the system. VA already for the proud preferred A was on all feels are for like the XXXX recent prime Briumvi of it the anti-CDXX award accomplishments Company-wide, announcement the incredibly is of off year. of firing start, to achieved as

as to able many our multiple introduce of split generate to Briumvi their to whom and excited between VA deep by incremental more offering a be appointments support great providers, be at Briumvi health sclerosis this and, with academic serve our cannot their course, the care of We a see way veterans revenue. additional We to time veterans, discount.

any As $XX for strong, a for received million, the the I'm robust quarter, TG. Briumvi was from that the was was revenue in to demand By million, excess partner. extremely the milestone includes first report and it and for which payments Briumvi were our measure, total revenue quarter over $XX for quarter of revenues pleased U.S. ex-U.S.

As mentioned of previously, increased starting to and strong in have patient to awareness commercial activities strategically team. size continuing, quarter results. increased first we investments significantly in investment our the I and late believe these XXXX have contributed our the

that broadly, More that our centers market perspective. to our becoming that, there. believe help We that feedback goal of achievable. infusion anti-CDXX to confidence continues and And profile the long-term on us be #X a has is should prescribed from dynamic share focused patients, team Briumvi our nurses best-in-class physicians, drive continues the from get

was annualized infusions the the generally trials, that than the is only trial dose starting in Phase only the delivered an anti-CDXX of as on a antibody in every anti-CDXX III can X-hour tolerated Phase less months Briumvi antibody achieve rate following III infusion is XX% relapse the Briumvi X-hour in Also monoclonal being with X.XX. of and be monoclonal X time. well given to infusion X-hour

Briumvi having data, Beyond by B-cell also enhanced for glycoengineered differentiated the engagement been and efficient clinical is immune cell design, effector depletion.

ability through MS, or the Briumvi to to highest to target of on and antibody-dependent B the highest other treat to induce compared used cytotoxicity. glycoengineering approved that the CDXX, the demonstrates found the has cellular binding cells data preclinical presented, the previously level has As anti-CDXXs affinity its

look have available. profile, data Briumvi's any, they contribution forward to than to further what, differences show if clinical these these evaluating and differentiated when preclinical we to assess to We will seek

to newly and Trademark during were XXXX. issued the excited there protection U.S. Briumvi quarter Patent from three We're that patents patent for share Office also through extending

With is runway, both autoimmune focused our the in MS for within on opportunities diseases. development as potential extended team expansion Briumvi, other as well

focused value. which year, initiatives To drive that future on this end, we significant believe could are Briumvi-related we three

the presented further evaluating the data is dosing who for Briumvi. switch updated a dose the of ACTRIMS X-hour and improving First Briumvi at we from XXX safety efficacy prior IV ENHANCE In the starting trial, milligram eliminating patients from the convenient March, conference, of anti-CDXX.

was Data presented full went skipped for a first as straight that XXX-milligram given dose to starting tolerated suggests and the infusion. well patients Briumvi the X-hour that dose

results additional year. the early safety we are to look These from forward to encouraging, this efficacy, continuing and data tolerability and study throughout present

and development this believe Briumvi. the for the opportunity additional a subcutaneous the is from of distinct CDXX Briumvi. represent Second could We market believe subcu market significant IV is

We studies throughout have are as bioequivalence this look to them and this additional enter forward providing to year. front on year preparing human the we updates

the year, look and a opportunity, stopping to indications. are there. of providing to sclerosis launch Briumvi Briumvi this goal of autoimmune first third, to expansion but look significant The evaluating we our not the we is throughout later trial outside we evaluating multiple forward And forward in represents autoimmune year. We updates Briumvi other believe

commencing expansion to diseases, has autoimmune we for partnership The allogeneic azer-cel, trial CDXX be all worldwide certain look Precision's and forward and this our year. autoimmune future a a best-in-class diseases to lies portfolio. first-in-class, a We to T recently BioSciences TG of azer-cel clinical CAR to acquire also other potential with indications. entered cell non-oncology Precision believe an license for a treatment We into in the therapy of the

our it first launch in also effort launch took progresses want of launch so first team to with the program make experienced, to around I in to worked from from look and Neuraxpharm the globe. in across is the to of Europe, as our their forward more timely closely enable Briumvi happen. then Germany. and and also the hearing which together at significant commercial multiple how their congratulate focused, countries the to on them motivated Europe occurred Neuraxpharm and quarter, The we partners I'm proud sale Transitioning team, everyone

acknowledge possible to care the TG want the take thank amazing I to MS. with and for Finally, It's TG-ers team. and that best patients attention entire to ensure see the focused experience

successes most lot on gratifying of about Briumvi firsthand calls from Briumvi. as HCP's we While time spent positive well of treatment the as day taking talking part is anecdotes numbers, experiences my their about a the patients hearing these and with patient's

the Adam Briumvi our update Waldman, Officer, U.S. Commercialization to to let ahead. me Adam, provide a hand call launch. Chief that, detailed commercial over go With on the

Adam Waldman

excited our insights in key Thank of the into to you, our revenue performance, first progress This all another was of in morning, and commercial our I'm performance continued guidance Mike, quarter good exceeding very quarter. provide everybody. metrics. strong

to with focus delivering you remains on I'm today. Our and unwavering, share Briumvi our patients progress pleased to

first XXXX, to see market. uptake in the of continue the Briumvi strong of In we quarter

for As our representing reported quarter-over-quarter. in growth sales were quarter U.S. net XX% press in Briumvi release, million, $XX.X first the

trends and updated quarter demand growing saw exceeded in $XX guidance early The our provided The throughout we the quarter million for the our as early Briumvi. late million $XX February. number as well we January of in reflecting to provided strong continued in guidance original first quarter,

the the beginning given payer is quarter particularly with dynamics. year first growth impressive challenges of This associated

In in see quarter-over-quarter during fact, time U.S. we growth frame. revenue only in were the market CDXX to this the MS

an hub Equally impressive challenges TG scripts in in job the exceptional the grow by over want our X,XXX received doing by seen insurance-related I patient potential saw quarter the is and new the we congratulate to that the also enrollments first with for approximately mitigating inherent on preparing XX%, impact. team quarter.

a educational both commercial virtually channels a patient initiatives; engaging targeted encompasses in strategy reach we've comprehensive and and providers, health leveraging that broader to audience. digital launch, Since implemented person; marketing care

care in value resulted increasing recognizing the with of patients. Briumvi, have efforts uptake health to brings Briumvi that Our providers

ensuring access us. for a Briumvi priority Concurrently, to patient remains top

We to reimbursement in support programs the introduced comprehensive assist accessing treatment have and on they the we patient exceptional continue to need. patients receive navigating challenges feedback

our growth. presence. and accounts saw increasing with were prescribers, the in prescribers approximately make new from number strides effective new which Through XXX gains academic to of impressive prescribers centers. penetrated marketing repeat sustained of significant successfully prescribers, we deployment, We in targeted We new also majority in both force and initiatives expanding continue and first driving the sales market quarter,

coming also adding by to new continued XX prescribers. we quarter. of XXX U.S. We XXX new unique and over adoption date, To centers from with centers, convert new broad in have prescriptions across the the accounts over Briumvi seen

patient types consisting treatments both quarter-to-quarter, treated CDXX to see patient that to naive mix to diverse we with fairly and and be a but those naive that patients largest treated, continue Encouragingly, were from those group mix and therapy. types, are agents. of This anti-CDXX of including also the non-CDXX all were previously that to switched consistent continue of previously

XXXX the strong headwinds. quarter Briumvi is guidance quarter off our continued and to our patient the start. far to a We quarter strong first achieved first show growth, really enrollments and first into revenue in hub new exceeded quarter-to-quarter record despite insurance

are available see We this momentum we And the quarter. million $XX targeting quarter. time, based Briumvi revenue on continue information we the for net to approximately into of second at have building the second

$XXX above to end our about we continue trajectory. In of Briumvi guidance year top therefore million. to $XXX $XXX million $XXX terms to believe of full Based original we year, we on of million the to the million raising confident trends, feel are tracking and guidance full current are the our

even opportunities on community. are broaden Looking the further expansion. ahead, an We believe we MS make to poised impact see promising growth greater and patient we our and reach for

We Briumvi's be choice IV relapsing and of MS the the profile will compelling market. continue remains eventually to therapy in believe very

and adoption believe have Briumvi care outstanding with confidence the our to in organization. with awareness providers, team our and precision, positive our experience They hard their driving efforts launch plan among are their I we and In for to contributing want and conclusion, dedication work. executed targeted the thank health

TG want we and need, also Briumvi do, families. patients in their more thank those for with are day to care MS certainly will living work but their health in improve to to I people outcomes for those to and trust providers motivated every focused to have to their work we to extremely we continue bring Together, the Therapeutics. continue and and

I'll Sean over With Power, our that, the CFO. call turn Sean? to

Sean Power

reported results, Earlier our our thanks, and us. on you, Media section XXXX first can joining morning, we financial Thank Adam, be which detailed & the website. Investors for viewed this quarter of everyone,

start a our morning, discussion revenue. with of I'll This

approximately We Briumvi license we pleased of revenue revenue Briumvi partner million our in in which, the $XX.X the U.S. $XX.X as of our of 'XX previously million included QX primarily which is net of includes milestone report for million to quarter royalty Also during total of are product the revenue. $XX ex-U.S. commercial first total $XX.X XXXX, mentioned, milestones, the million first consists from other revenue, EU. approximately launch and of received

'XX, controlled Our OpEx remained quarter onetime some and discussed of line first during previously in well ranges. has with despite the charges,

of the to 'XX, agreement our For $X.X which our in-licensed operating with million quarter research of BioSciences the approximately expenses charges to first expenses and azer-cel development Precision onetime for program. $XX were related approximately includes million,

of our associated with driven the in development we a expenses, also increase and quarter by During first 'XX, costs work. R&D ublituximab manufacturing subcutaneous saw modest development

the and quarter million in to during million reported $X.XX loss reported the net or share $XX.X approximately of well-controlled per first On of per quarter we back 'XX, net share comparable the compared of revenues XXXX. during or $XX.X of $X.XX a loss a approximately the modest OpEx,

guidance, ended positivity. the with standpoint, previously our a 'XX. cash sufficient $XX cash, and with down equivalents of million position, our cash fund less coupled From than We operations with from we securities, quarter provides our revenue cash QX current guided million in first investment $XXX.X expense us flow cash to capital and believe to

With call turn the Q&A. that, to begin I operator over to the will now the conference

Operator

Michael comes question [Operator of with Evercore. first Instructions] line DiFiore Our from the

Michael DiFiore

on all A this projects me. great the for congrats And couple quarter.

we follow-ups. Regarding sales details? two when in Neuraxpharm early, expect I very EU, it's to know And but have I offering could begin

Michael Weiss

Yes.

they'll so or to backed, details, I private guidance my think a information off. of don't a public They providing anticipate way in are public any be company, providing private So knowledge. long I terms equity we're Neuraxpharm

different anything your Adam, side? from

Adam Waldman

No, no. Nothing there. to add

Michael DiFiore

could year Fair on recently heavily in 'XX And fiscal okay. this color that was Briumvi's you other raise two segment? or the Okay, my questions I And rebating due know to any you how increased enough. are, VA said guidance contract? announced provide pricing discounted. it's much of

Michael Weiss

ahead. Adam, Yes. go

Adam Waldman

-- effect really was couple factored One, raise revenue the really for Yes, not Sure. won't VA reasons. this a until was of go the June. in into

to really patients Second, it gradual this will will increase have at on. opportunity best. of year only in Patients a as first the be have infusions sort new the get two

raised we be guidance. in the the it we're The that will really seeing. looked trends raising a and factor on that a guidance way it was So gradual at increase, our wasn't based demand

think public. vial. that's $X,XXX there As a far about I a roughly about and out discount, as pricing, We XX% offered

Michael DiFiore

And Great. this. at presented my Cohort Okay. data enhanced infusion most have patients is or the recent In in the down X had last question to ACTRIMS, of cut their interrupted. three slowed

long for? clinical were these features to And would patients Any this? these could explain any slowed or How patients? down unique interrupted color of on there these that infusions

Michael Weiss

So there were no, to think I pretty I was about the all And but X-hour don't done anyway. infusions we've the reasonably think particular anything modest. the patients, close

It did infusions. overall, But was patients think basic think I I anything don't well. those be there. it tolerated well worried to no, So was just about that there's typical and is stuff of

Operator

White of question Our Wainwright. next line from H.C. comes Ed with the

Edward White

Congratulations results. on the

you So Was to a the VA it Adam. the just said -- XX% clarify contract, just discount? on what

Adam Waldman

Yes.

Edward White

brought wanted produce be able I I -- this to opportunity think Is your the or before, sales force? on this And Okay. so-called with address data you'll has again. OCREVUS. about to with this something up the address somehow in you it that Thinking been crap-gap but just potential

Michael Weiss

Yes.

to of study. trying as show, as gap in we through ENHANCE So capture able terms the crap mean, data being and much I can to we're

think XX-ish as to is I Maybe they're ENHANCE into the coming the about trial. number X/X percent. crap-gap report XX

whether have they're end. of anecdotal seeing we'll at on the some reported, about try Hopefully, information not information capture patients So the to or some least that we'll crap-gap. back

we've It's patients. study. parse studies effect for measure, that hard objectively ENHANCE thing will to so no it to to that the conduct, is no the There's certainly a And out do -- we there's whether scale crap-gap. best we -- we'll challenging try within measure and we but whatever the changed can

Edward White

there, indications, other time Okay. that? do How market? does approval factors And come just plenty potential to size potential outside prioritize thinking sort but of you have about of of how potential ranking I'm in are you -- MS? when you of sure or in where the

Michael Weiss

Yes. on think, in MS outside lupus Briumvi focused previously, And at look, sort I we things we've indications, indications. of RA I more probably and would some of larger for mean, like azer-cel. as be we're looking niche said

Operator

Our next question comes from Song Jefferies. the line of Roger with

Jiale Song

couple have from of is so have of results. hub us. you then so repeat XQ since few is And and the your seeing? infusion the just to Congrats a quite patients a given most new how characterize One quarters rate questions the been understanding capturing you launch, would you

Michael Weiss

do to Yes. ahead on that Adam, want you go one?

Adam Waldman

Yes.

So patient are yes, you patients we're only. here, the hub just giving that to numbers reconfirm new

-- So there. was that just question to think your I

of our still far better XX%, we about continue persistence we're And however, as line see XX-week but and that would then -- slightly data, or our XX. see, early expectations as the is with that maybe we in the say persistence, -- continue than we in data the we to week

pretty it. feel about we good So

right the what at early, slightly it's to But is we'll we or in it. now, ahead of expected. data maybe line Although look continue

Jiale Song

good. you are and around And provider is XXX centers. XXX now XX% then Excellent. having so health

So to understanding you targeting -- you plan you where top MS launch, accounts to patients. with covering when XX% start to XX XX% are

you do outreach? that million? still the $XXX that's curious, the still the case, achieve that And then provider from will Just expect goal or center million the then when $XXX if is for you

Adam Waldman

Yes, yes.

done opportunity and, of even use now, understand think We've got the So for new with of we certainly really what's I adoption broad more course, with accounts I goal our it's adoption think the say deepening in right that if but more see prescribers I'll prescribers. just good. I current our question, new prescribers. and terms we've

new the as in a prescribers good news we pretty both good new accounts in prescribers The saw quarter and at clip. pretty good increases repeat a at adding and clip

we're good at good continuing about day So make but and feel where have We're progress it. we feel about to now. opportunity, every right certainly

Jiale Song

last question related financials. Okay. the One to

this for the $XXX the So you're earlier year, OpEx guiding as I million think year.

the is coming to for expanding for ] guidance expenses also to that launch curious and your still now? want And then about pipeline. you [ Just confirm, given continue years the the

Michael Weiss

think Precision. little Sean, said $XXX a I you track even which wiggle million there. at we $XX And million I'll look if the we mean, we But had and room change, had first -- Yes. It on a and first OpEx. to the jump approximately $X I take crack. onetime change, we're yes, But was to well gives in. quarter, in million and us

So for still only million around the base $XX quarter. OpEx the is

grow, That X, us times that still to and $XXX. well gives under growing. you're we multiply you room So are the

my in good team, to our But to and on money pretty we're said I we're sit from we're think, today, I where in Like programs. adding strategically spend shape. awareness remarks, we prepared continuing patient

Sean, any more there? details

Sean Power

No.

covered you've Mike. pretty it think I well,

Operator

of question Our Matt next comes from line Thalmann. the Ladenburg Kaplan with

Matthew Kaplan

quarter. the on Congrats

for So maybe Adam.

In give naive, in terms patients where of the starts, in patient us coming and new a getting they're little bit of you're detail of these switch terms that background terms you from? from new more can

Adam Waldman

Yes. Thanks, Matt.

would CDXXs, non-CDXXs, as out have patients specific the What as group is I we switching we not the like we breaks are KESIMPTA. patients biggest out. of but given from also patients OCREVUS it patient percentages well and said representation that treatment-naive say good have or exactly So from how from switching is

So of sort of any getting there patient boluses staying we're a of time. quarter-to-quarter. group -- importantly, we're getting big -- think no over encouragingly, nice that wasn't and, certain of diffused patients a consistent we diverse There's sort group

consistently groups. all seeing of those representation we're three So from

Matthew Kaplan

call, I as formulation. guess, more billion. the is That's opportunity guess, profile, said your recently the of differentiated potential $X in on I what's And question of guess, then, than terms opportunity? your with subcutaneous see assessment opportunity Briumvi I the subcu Roche the they helpful. they for Okay. subcutaneous the

Michael Weiss

look, nice out speak probably $X today. of done subcu probably over Novartis is I'll broadly, created really And I carving folks Yes. mentioned, Novartis let growing I'll and job it. in. chime and a They've Adam have the mean, think, a billion Roche as I at market.

there's nice a So market there.

And a is that with mean, yes, product. market I goal profile our come competitive very into to

the said a a bulky got, auto-injector X we've relatively one and we got relatively a month, on We've product every the understand months. we've elegant once As parameters. previously, hand,

we're and get product in is to middle, to it an the Somewhere think we try design, optimal going there.

I So our we're sit at best take seeing today, to where just crack think it. from we're and going opportunity, we

Adam?

Adam Waldman

Mike. to else Nothing really add there,

Michael Weiss

All right.

Sorry about that.

Operator

Our with next the comes of from Mamtani question Mayank line Riley B. Securities.

Mayank Mamtani

Congrats on strong quarter. a

I also in Adam, Sorry, say missed revenue this. should second maintenance patient I to new you stacking the up was think curious from and you revenue effect patients? up how we if starts to hear Did that be. expect split that you split half, how between And

net. And follow-ups. some before, if would can other free helpful on Anything you modeling. also I a of comment have you've metrics percentage, think that drug to about the full provided then be gross as year we couple on And

Adam Waldman

share on it. from duration this a sticky a goes there the years. will patients good. miss of of really X effect We revenue, are revenue continue is on, didn't that Patients -- a didn't will very pancaking will versus We -- new didn't -- an any as continuing that do big -- average is We be perspective. drug share on a and you this is time duration is a patients Yes. where specifics driver to market feel

over that see pancaking will time. effect you So

that's best have I the for that question. that So

I was think free question your drug. other

did down. said before, expect come we drug free I to rates As

drug down. seeing rates are free We come

XXXX, about the in right XX% it think first I I was is XX%. think we're quarter, about our now, in we're XX%. about earlier From --

in XX% So quarter. the

up XXXX. is is a what previously go to gross of from down is to think XX%, standpoint, use I gross number remainder But to good our we net approximately for said XX% And a net quarter-to-quarter. and then from will probably the

Mayank Mamtani

Mike, know learn about year-end percentage, exit was are I think market curious as provided. That's helpful. that you don't which, of guidance you how thinking think if updated full And the year, for Again, market then in total NRx your share. to I you I just

assumes curious give that some tracking the patients hear to patient. of You're on share? total you about think either you just how anti-CDXX market that in Could -- share XX%. us at $XXX color what obviously market how that in terms But million within midpoint drug terms of or RMS class

Adam Waldman

any We the Yes. increase growth. depth to to specifics. probably here use mean, continued breadth continue prescribers. is use see for Mayank, goal I'm opportunity not our and going of I add to into the the and of get the new

in on we continue job doing in of confident very We trends seeing. going market, on we're very based Briumvi a of we're the continued growing to usage guidance feel confident going feel that focus trajectory. And here, feel And the We we're the to it. very great feel across the forward. -- in and we growth confident obviously, demand our

Mayank Mamtani

ahead. Go

Michael Weiss

Yes. split, on question old. I'm first going to chime you asked versus new revenue about in just the the

starts. I the -- to the Just later we're in actual know be ongoing by years, that numbers, but patients. I we're mention be to by new not will just worth the it's going early we stacking the or driven think driven In providing years,

where new But on still, time, at over We're not take right? as in the patients quarter, going if on long our how role sales you a say, competitive has the on been the their particular revenue time, I'd new based So on probably sort any be opposite majority stack market continuing patients, still probably continuing patients commanding to up. the we're IV for of vast the are of in CDXXs starts. reliant the our look

Mayank Mamtani

that size last Yes. bodes well for And subcu of guess, the I on question target profile, product pancake Mike. that that Yes. downstream.

human that now in we as what subcu attributes data OCREVUS feedback, the there, to design are we Just some like at Mike, the think differentiating out curious, launch, profile as the that would is just that the would look know now for about product mind be profile? and all you helpful was of study, even you KOL how bioequivalent understand what

Michael Weiss

Yes.

at is subcu true the product today. look, not a administered OCREVUS home patient So

even created as -- or yet but available created, studied my knowledge. is that or not be as to to far be So

still So that's to come. yet

our goal a more something that along lines with to I what done the product, was of is have mean, ofatumumab. again, is patient-administered, patient-friendly

So here I being to that profile of and up lot room the markets We come know the how they accomplishes convenient in. think with of both and thread easy product goals there's to much don't are a needle a use.

Operator

question next Cantor the Agrawal from Fitzgerald. Our comes Prakhar line of with

Prakhar Agrawal

the And quarter. congrats on

So just Briumvi land following for on the to up dosing on subcu could what's case trying your I'm assumption frequency the question. where base understand, subcu Briumvi?

I guess, still the reason I'm ends the once a you asking is have ahead one with up go development? if being I it subcu And month, more. would

Michael Weiss

the I don't that's to mean, we going I Yes. be think would, is bottom necessary. I line probably but think

know likely. has think in that I So like mean, early to feel make tell. I a good opportunity a the don't if scenario I go a to got we've we'll we that's And it's yes, market, again, forward. that that, something But is dent

that a concerned some it the Obviously, less has But -- that's the duration, a an be once market. has that in impact could not so and have could than certainly, on in issue I'm here. math do probably less something concentration frequency. that that, And less impact month we'll and

Prakhar Agrawal

subcu And be to patients dosed Briumvi? expect when you for do

Michael Weiss

We first to within of patients dosed half first hope this would have the year.

the in here. next hopefully, So months few

Prakhar Agrawal

lot side, of your indications. seeing CDXX lastly And CDXX What's other and on we're a versus from my antibodies it. data view CDXX? autoimmune Got on

could a let's targeting of compared that the B-cell broader CDXX theory coverage CDXX. there say, obviously, is achieve compartment And to, a

And get do you have there. a wanted your early-stage to perspective CDXX just So pipeline? in

Michael Weiss

do we mean, have a azer-cel I is It T CAR It's yes, CDXX. our CDXX. a So therapy.

if all CDXX think is we coverage think it's broader to is great in a positive We So settings. the target. know a hard

that by talk diseases CDXX some helpful. are driven. one maybe be or may frequently in more cells may NMO that CDXX characterized CDXX potentially plasma that impacted are or about expressed quite that as by be There is folks

think think CDXX, areas cells. be is the hard and hits when CDXX matured And most are CDXX opportunity they hits the going be B may where diseases. to in in distinguish overall, helpful. overall -- we So CDXX we pre-B-cell there B in to addition to hit cells, CDXX But

So may in terms there. of see a you difference recovery,

things But a there's difference. going when to think standpoint, don't I diseases, from CDXX. an think to material lot you I So you're know activity CDXX balance a versus of see in about if most

Prakhar Agrawal

even my have in stage, CDXX guess, I preclinical? antibody, was about one a Yes. antibody not T. the you CAR I clarification. asking CDXX the Do early

Michael Weiss

a don't, find this don't. to interest be we us I of product time. to that We don't at

Operator

question from of comes next with Our line Joseph the Eric JPMorgan.

Noah Eisenberg

This is for Eric. exclusive secured there on the were just other the with Noah similar VA? were just if to wondering you opportunities We that contract procurement

Michael Weiss

Adam?

Adam Waldman

you Not question. Could sure clarify? understand I the

Noah Eisenberg

are We're for access going just Yes. forward? there opportunities wondering if other exclusive with [indiscernible] contracts other providers

Adam Waldman

Got got Okay. you, you.

on There don't -- I any time have updates Understood. Okay. at question. this that

Operator

Corinne our line comes of Jenkins Sachs. question with the next And Goldman from

Corinne Jenkins

support or X SG&A versus the close profitability in the your or So quarter are thinking of to development? extending given [indiscernible] like you've maybe a probably are guidance guidance. or profitability through it's revenue versus couple R&D questions from One, us. the ramping How next future of stated you that and to OpEx guys you kind reaching spend

is from to enter able left formulation else before you're to what on do then technical perspective a the clinic? the areas, subcutaneous And

Michael Weiss

Sure.

budget profitability, mutually -- million exclusive year. Briumvi are We've approximately questions points, about don't that or So increased we we continue to I in you the in an thinking those asked the have for the to right? launch. have invest OpEx think will noted -- So we $XXX

to I there's room So think some grow. even there

the we we've opportunity. From Briumvi to that opportunities. And among azer-cel continue additional interested build and opportunity, product the for similarly, standpoint, look said we'll a continue to external are

the that we And R&D it platform. may plan as grow don't to I future So continue of Briumvi EPS I don't our our know think I efforts something team do our exact and -- with think that I numbers. we're continue the profitability fixated becomes interest. But and on is exclusive. to know

versus company, overall modest, structure a our our pretty all, but an think, is kept most most, ship. other cost companies, not as But I lean -- pretty and we've

consequence than the probably profitability would, So companies I given be most at of that circumstances. is think sooner we'll the

the entering I much before over In terms hurdles. think technical technical aspects of clinic, of most the the we're pretty subcu

believe, get technical next think be working so. the there's able all I don't into there's think program. be And any I I continuing think filtering months what just will to into continued right now. hurdles X the improvements the clinic, to we're on, clinical make or But effort in we'll a in I which

Just going. getting and get --

Operator

reached that, end Weiss question-and-answer of back our like have any with would closing turn the over the And We for to comments. to floor session. Mike I

Michael Weiss

to see has Well, able the Hopefully, on what's to thank going at you, enthusiasm company. the okay, want here everyone been have joining today. I just and so TG we with excitement everyone that everybody. Great. Thank and for us

were -- we We extremely the more look everything the as went forward our move quite into and first year. good, of continuing quarter push to remainder even We the forward we forward think to And in was opinion. achieve well.

into thank to want does we their clinicians and put Again, everyone thank whole importantly, we for patients support. The trust TG. the who their Most definitely it. team appreciate

for and With thank that, I'd great like a joining have us, day. to everyone

Operator

teleconference. This concludes today's

your Thank this your at you participation. for may time. lines disconnect You

TG Therapeutics (TGTX) 1 May 242024 Q1 Earnings call transcript